Cue Biopharma, Inc.
CUE
$30.50
$0.501.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 38.53% | -74.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 38.53% | -74.09% | |||
| Cost of Revenue | 658.28% | -59.85% | |||
| Gross Profit | -5,614.49% | -111.83% | |||
| SG&A Expenses | 911.72% | 14.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 764.98% | -44.71% | |||
| Operating Income | -1,535.19% | -373.90% | |||
| Income Before Tax | -2,856.10% | -348.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2,856.10% | -426.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,856.10% | -426.69% | |||
| EBIT | -1,535.19% | -373.90% | |||
| EBITDA | -1,727.37% | -281.98% | |||
| EPS Basic | -2,141.18% | -344.63% | |||
| Normalized Basic EPS | -2,136.83% | -288.15% | |||
| EPS Diluted | -2,141.18% | -350.31% | |||
| Normalized Diluted EPS | -2,136.83% | -292.49% | |||
| Average Basic Shares Outstanding | 31.89% | 33.56% | |||
| Average Diluted Shares Outstanding | 31.89% | 30.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||